Antineoplastics
1
Reactions 1029 - 27 Nov 2004 S Antineoplastics Acute myeloid leukaemia and myelodysplastic syndrome: case report A 41-year-old woman developed acute myeloid leukaemia (AML) after antineoplastic therapy for peripheral non- Hodgkin’s lymphoma. During remission of AML, she developed a myelodysplastic syndrome. The woman initially received doxorubicin, cyclophosphamide, vincristine, prednisolone, mitoxantrone, etoposide and vindesine, with partial response. She then received several combination antineoplastic therapies, including etoposide, cisplatin, carboplatin, cytarabine, enocitabine, ranimustine, procarbazine and bleomycin, with subsequent complete remission. She had received doxorubicin, cyclophosphamide and etoposide cumulative doses of 400, 5500 and 4500mg, respectively [duration of treatment not clearly stated]. Approximately 4 months later, she developed a non-Hodgkin’s lymphoma of the brain and was treated with surgery and whole-brain irradiation. At this time she developed anaemia and thrombocytopenia, and investigations revealed acute myeloid leukaemia. The woman was treated with daunorubicin, enocitabine, mercaptopurine and prednisolone, and received maintenance therapy with daunorubicin, aclarubicin, cytarabine, enocitabine, mercaptopurine, etoposide, vindesine, vincristine and ranimustine for 3 years. Approximately 3 years after treatment discontinuation, she developed thrombocytopenia, and investigations revealed a myelodysplastic syndrome. She was asymptomatic initially but, approximately 2 years later, developed petechiae and gingival haemorrhage. Over the next year, the number of circulating megakaryoblasts and the frequency of haemorrhagic events increased, and despite treatment with cytarabine ocfosfate and platelet infusions, she subsequently died due to cerebral haemorrhage. Sakai C, et al. Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation developing during complete remission of therapy-related acute myeloid leukemia with t(8;21). Internal Medicine 43: 582-586, No. 7, Jul 2004 - Japan 807217849 1 Reactions 27 Nov 2004 No. 1029 0114-9954/10/1029-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1029 - 27 Nov 2004
SAntineoplastics
Acute myeloid leukaemia and myelodysplasticsyndrome: case report
A 41-year-old woman developed acute myeloid leukaemia(AML) after antineoplastic therapy for peripheral non-Hodgkin’s lymphoma. During remission of AML, shedeveloped a myelodysplastic syndrome.
The woman initially received doxorubicin,cyclophosphamide, vincristine, prednisolone, mitoxantrone,etoposide and vindesine, with partial response. She thenreceived several combination antineoplastic therapies,including etoposide, cisplatin, carboplatin, cytarabine,enocitabine, ranimustine, procarbazine and bleomycin, withsubsequent complete remission. She had receiveddoxorubicin, cyclophosphamide and etoposide cumulativedoses of 400, 5500 and 4500mg, respectively [duration oftreatment not clearly stated]. Approximately 4 months later,she developed a non-Hodgkin’s lymphoma of the brain andwas treated with surgery and whole-brain irradiation. At thistime she developed anaemia and thrombocytopenia, andinvestigations revealed acute myeloid leukaemia.
The woman was treated with daunorubicin, enocitabine,mercaptopurine and prednisolone, and received maintenancetherapy with daunorubicin, aclarubicin, cytarabine,enocitabine, mercaptopurine, etoposide, vindesine, vincristineand ranimustine for 3 years. Approximately 3 years aftertreatment discontinuation, she developed thrombocytopenia,and investigations revealed a myelodysplastic syndrome. Shewas asymptomatic initially but, approximately 2 years later,developed petechiae and gingival haemorrhage. Over the nextyear, the number of circulating megakaryoblasts and thefrequency of haemorrhagic events increased, and despitetreatment with cytarabine ocfosfate and platelet infusions, shesubsequently died due to cerebral haemorrhage.Sakai C, et al. Therapy-related myelodysplastic syndrome with trisomy 1q due toder(1;7) and megakaryoblastic proliferation developing during complete remissionof therapy-related acute myeloid leukemia with t(8;21). Internal Medicine 43:582-586, No. 7, Jul 2004 - Japan 807217849
1
Reactions 27 Nov 2004 No. 10290114-9954/10/1029-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
